Discovers and develops oral therapeutics for rare endocrine diseases. Focuses on endocrine-related tumors, including carcinoid syndrome and neuroendocrine tumors. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 63% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Business Quality: Profit power and business quality trail similar companies in the sector.
Growth: Sales growth trails the sector average.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $7.7M a year. A small number, but proof the product has real buyers.
A loss of $465.3M against $7.7M in annual sales.
At the current pace of spending, the cash lasts about 2.2 years. After that, the company needs to find new money.
Over the last 12 months, executives reported 132 sells against just 43 buys. Not an alarm bell by itself, but a number worth watching.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.